Haim Zaltzman
Partner
New York / San Francisco / Silicon Valley
haim.zaltzman@lw.com
PRACTICES
- Banking
- Capital Markets
- Emerging Companies & Growth
- Private Equity Finance
- Project Development & Finance
- Technology Transactions
INDUSTRIES
- Healthcare & Life Sciences
- Technology
EDUCATION
- BA, Stanford University,
- JD, Harvard Law School,
- MA, Russian Academy of Sciences,
LANGUAGES SPOKEN
- English
- Hebrew
- Russian
PROFILE
Haim Zaltzman, Global Vice Chair of Latham's Emerging Companies & Growth Practice, focuses on private capital, finance, and other corporate transactions, primarily in the healthcare, life sciences, and technology fields. Haim is a member of the firm's Strategic Client Committee and Private Capital Practice.
Haim frequently represents borrowers/issuers, sponsors, and financial institutions in private capital transactions, including:
- Technology growth financings (venture, structured, ABL, ARR, CARR/bookings, milestone-based, Up C, SPAC-related, and other structures)
- Direct lending transactions (private equity acquisition financings, cash-flow, ARR, CARR, liquidity, and other structures)
- Life sciences intellectual property monetization transactions (IP-backed debt, royalty buyout, synthetic royalty, revenue participations, R&D financings)
- Leasing, crypto/bitcoin, securitization, and other similar asset-based transactions
- Structured equity, pre-IPO debt and equity financings, and similar private capital transactions
Haim holds leadership positions with the Chinese American International School and the American Jewish Committee.
Haim has also been featured on CNBC, The Information, Bloomberg, The Washington Post, CFO Magazine, The Recorder, Law360.com, The Daily Journal, the International Financial Law Review, and VCExperts.com for his debt experience.
EXPERIENCE
Haim's representative transactions include:
- Hundreds of growth companies and their sponsors in every kind of financing
- Multiple direct lenders and investors in the life sciences space, including venture, structured, royalty, and other IP-related financings
- Various investors in late stage, growth capital, including pre-IPO converts, SPAC financings, redeemable and non-redeemable preferred, SPAC-related structures, and other secured and unsecured financings, to technology companies
- Various private equity and venture capital firms in debt and equity financings of all types
- Multiple technology and life sciences companies and sponsors in deSPAC transactions
- Multiple lenders and companies in securitization-related transactions
Prior Professional Experience
- Former Editor of the Stanford Journal of International Relations
- Fulbright Scholar in Russia
- Prior to Latham & Watkins, attorney in the New York office of Skadden, Arps, Slate, Meagher & Flom LLP
Thought Leadership
- Extending Your Reach: New Approaches to Values-Based Compliance and Contracting, January 5, 2023
- Emerging Growth Debt, Venture Capital General Counsel Meeting, Boulder, Colorado, March 29-30, 2017
- Financing Emerging Growth Companies with Debt, Webcast, May 4, 2017
- The Healthcare & Technology Industries’ Burgeoning Emerging Growth Debt Market, March 13, 2015
- When Venture Funding is Debt, Not Equity, June 22, 2011
- After the Credit Crunch: Venture Credit Facilities at the Term Sheet Stage, June 20, 2011